Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer
- PMID: 16873430
- DOI: 10.1093/annonc/mdl175
Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer
Abstract
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer in the world. At present several therapeutic approaches, including surgical removal, chemotherapy and radiotherapy, are used. Yet a significant number of patients relapse, often with metastases. In an attempt to improve treatment of SCCHN new targeted therapies are emerging. Among them special interest has been devoted to agents that act on the epidermal growth factor receptor (EGFR) and other receptor tyrosine kinases, or the signal transduction routes used by these receptors to induce tumour cell proliferation. Such treatments include monoclonal antibodies and small molecule inhibitors of either the intracellular tyrosine kinase activity of these receptors or relevant signalling intermediates. Here we review the biological bases of these new targeted treatments, with special emphasis on the clinical results that point to an implementation of these drugs into the therapeutic armamentarium against SCCHN.
Comment in
-
Intriguing issues of EGFR targeting in head and neck cancer.Ann Oncol. 2007 May;18(5):962. doi: 10.1093/annonc/mdm117. Epub 2007 Apr 17. Ann Oncol. 2007. PMID: 17442660 No abstract available.
Similar articles
-
Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers.Front Biosci (Landmark Ed). 2013 Jan 1;18(2):520-42. doi: 10.2741/4118. Front Biosci (Landmark Ed). 2013. PMID: 23276940
-
Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.Br J Cancer. 2007 Feb 12;96(3):408-16. doi: 10.1038/sj.bjc.6603566. Epub 2007 Jan 16. Br J Cancer. 2007. PMID: 17224925 Free PMC article. Review.
-
Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.Hematol Oncol Clin North Am. 2015 Dec;29(6):1011-32. doi: 10.1016/j.hoc.2015.07.007. Hematol Oncol Clin North Am. 2015. PMID: 26568545 Review.
-
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.Am J Clin Oncol. 2016 Aug;39(4):396-406. doi: 10.1097/COC.0000000000000283. Am J Clin Oncol. 2016. PMID: 26967327 Review.
-
Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors.Curr Cancer Drug Targets. 2007 Nov;7(7):666-73. doi: 10.2174/156800907782418293. Curr Cancer Drug Targets. 2007. PMID: 18045071 Review.
Cited by
-
The role of EGFR-targeting strategies in the treatment of head and neck cancer.Onco Targets Ther. 2012;5:127-31. doi: 10.2147/OTT.S31863. Epub 2012 Jul 27. Onco Targets Ther. 2012. PMID: 22888261 Free PMC article.
-
Promising new molecular targeted therapies in head and neck cancer.Drugs. 2013 Mar;73(4):315-25. doi: 10.1007/s40265-013-0025-3. Drugs. 2013. PMID: 23440867 Review.
-
Promising newer molecular-targeted therapies in head and neck cancer.Drugs. 2008;68(12):1609-19. doi: 10.2165/00003495-200868120-00001. Drugs. 2008. PMID: 18681486
-
Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.Mol Cell Proteomics. 2011 Dec;10(12):M111.011635. doi: 10.1074/mcp.M111.011635. Epub 2011 Sep 28. Mol Cell Proteomics. 2011. PMID: 21955398 Free PMC article.
-
The molecular pathogenesis of head and neck cancer.Cancer Biol Ther. 2010 Jan;9(1):1-7. doi: 10.4161/cbt.9.1.10905. Epub 2010 Jan 9. Cancer Biol Ther. 2010. PMID: 20038820 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
